Smoking cessation treatment for COPD smokers: the role of pharmacological interventions

Submitted: November 26, 2015
Accepted: November 26, 2015
Published: November 26, 2015
Abstract Views: 2388
PDF: 1422
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Because stopping smoking is such a pressing necessity for COPD smokers physicians should use smoking cessation treatments aggressively. For optimal efficacy smoking cessation in COPD smokers should combine behavioral and pharmacological treatments. Three types of pharmacological treatments are proven to be safe and effective: Nicotine Replacement Therapy (NRT), Bupropion and Varenicline. Use of NRT, bupropion or varenicline, single or in combination, at standard doses or at high doses, for 8-12 weeks or for more than 6-12 months have proven to help these patients to quit. For optimizing efficacy these medications can also be introduced some weeks before actual quitting. In COPD smoking patients that are not interested in stopping completely or abruptly these medications can be used to aid cessation in a more gradual way. Pharmacotherapy to aid cessation in COPD smokers have proven to be highly cost effective.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

How to Cite

Jiménez-Ruiz, C.A., and K.O. Fagerström. 2015. “Smoking Cessation Treatment for COPD Smokers: The Role of Pharmacological Interventions”. Monaldi Archives for Chest Disease 79 (1). https://doi.org/10.4081/monaldi.2013.106.

Similar Articles

<< < 54 55 56 57 58 59 60 61 62 63 > >> 

You may also start an advanced similarity search for this article.